# A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

> **NCT00516373** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 98 (actual)

## Conditions studied

- Ovarian Neoplasms
- BRCA1 Protein
- BRCA2 Protein

## Interventions

- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)

## Key facts

- **NCT ID:** NCT00516373
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-11
- **Primary completion:** 2008-12-17
- **Final completion:** 2023-04-26
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516373, "A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00516373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*